Evidence map›Paper›PMID 37746768›Full record

ArticleEpilepsia2024

4-Phenylbutyrate promoted wild-type γ-aminobutyric acid type A receptor trafficking, reduced endoplasmic reticulum stress, and mitigated seizures in Gabrg2

Wangzhen Shen, Carson Flamm, Aiden J Delahanty, Emmett Casteel, Marshall Biven, Melissa B DeLeeuw, Sarah Poliquin, Gerald Nwosu, Karishma Randhave, Jing-Qiong Kang

Open access · bronzeAbstract read
In one paragraph

Article in Epilepsia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. 4-Phenylbutyrate Rescue inbioRxiv : the preprint server for biology · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Proteostasis regulation of GABABiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025
    Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Wangzhen ShenDepartment of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Carson FlammDepartment of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Aiden J DelahantyDepartment of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Emmett CasteelDepartment of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Marshall BivenDepartment of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Melissa B DeLeeuwDepartment of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Sarah PoliquinDepartment of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Gerald NwosuDepartment of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Karishma RandhaveDepartment of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Jing-Qiong KangDepartment of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0003-1079-5436
Vanderbilt University Medical Center · USMeharry Medical College · US

Funding

Overall: Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Center at VanderbiltP50HD103537 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jeffrey L Neul · 2020 to 2026
$10.3M
Promoting Protein Trafficking with 4-phenylbutyrate to Treat Genetic EpilepsyR01NS121718 · NINDS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jing-Qiong Kang · 2022 to 2026
$2.2M
Altered synapse formation and function in a novel Dravet syndrome mouse modelR01NS082635 · NINDS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KANG, JING-QIONG · 2013 to 2017
$1.7M
NICHD NIH HHS P50 HD103537NINDS NIH HHS R01 082635NINDS NIH HHS R01 NS082635NINDS NIH HHS R01 NS121718
6 · The paper itself

Abstract

objectiveγ-Aminobutyric acid type A (GABA

methodsWe used biochemistry in conjunction with differential tagging of the wild-type and the mutant alleles, live brain slice surface biotinylation, microsome isolation, patch-clamp whole-cell recordings, and video-monitoring synchronized electroencephalographic (EEG) recordings in Gabrg2

resultsWe found that PBA reduced the mutant γ2(Q390X) subunit protein aggregates, enhanced the wild-type GABA SIGNIFICANCE: This research has unveiled a promising and innovative approach for treating epilepsy linked to GABA

Indexed as

Epilepsies, MyoclonicEpilepsyPhenylbutyratesAnimalsEndoplasmic Reticulum Stressgamma-Aminobutyric AcidHumansMiceReceptors, GABAReceptors, GABA-ASeizures4-phenylbutyric acidGabrg2 protein, mousegamma-Aminobutyric AcidPhenylbutyratesReceptors, GABAReceptors, GABA-A4-phenylbutyrateepilepsyER stressGABAA receptorsGabrg2+/Q390X knockin mice

Identifiers

PMID37746768
PMCPMC10842976
OpenAlexW4387001937

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.